In last few years, therapeutic antibodies have gained maximum share in the US cancer therapeutics market. Their ability to specifically target the antigens on cancer has enabled the development of several targeted therapies. Further, advancement in the field of biotechnology has also led to development of new generation therapeutic agents. To date, several modalities of therapeutic antibodies including monoclonal antibodies, bispecific antibodies, antibody drug conjugates, and radiolabelled antibodies have been approved by US FDA which has shown robust response in the market. These are indicated for the management of several cancers including breast cancer, lung cancer, blood cancer, colorectal cancer, and other malignancies.
In 2021, immune checkpoint inhibitors segment hold the maximum share in the US cancer antibody market owing to their unique mechanism of action. The immune checkpoint inhibitors act by blocking the checkpoint protein, which are responsible for the prevention of cancer cells from the action of immune system. To date, 8 immune checkpoint inhibitors have entered the US market which is showing increasing sales every year. Apart from this, researchers are also evaluating other immune checkpoint including LAG-3, TIGIT, and others which are mainly present in clinical development. Relatlimab developed by Bristol Myers Squibb is a potential LAG-3 inhibitor which is expected to gain approval in market in March 2022, thus further boosting the growth of this segment during the forecast period.
The US cancer antibody therapeutic market is highly crowded and consists of several key players including Novartis, Amgen, Pfizer, Gilead Sciences, AstraZeneca, Bristol Myers Squibb, among others. For instance in 2021, Exelixis and Invenra have extended their discovery and licensing partnership to include 20 more oncology targets for multi-specific antibodies, antibody-drug conjugates, and the development of other biologic candidates. Further, AbbVie and I-Mab also announced collaboration for the development and commercialization of lemzoparlimab (also known as TJC4), an innovative anti-CD47 monoclonal antibody internally discovered and developed by I-Mab for the treatment of multiple cancers. In addition, the two partners have the potential to expand the collaboration to additional transformative therapies.
Global Information, Inc. [JASDAQ 4171] https://www.giiresearch.com/ Toll Free (US): +1-866-353-3335 Outside US: +1-860-674-8796 Europe (Belgium): +32-2-535-7543 Email: firstname.lastname@example.org